title: The actin binding domain of the epidermal growth factor receptor is required for EGF-stimulated tissue invasion.
abstract: NIH-3T3 fibroblasts expressing epidermal growth factor receptors (EGFRs) lacking the actin binding domain (ABD) were analyzed for their EGF-induced capacity to invade a bone marrow stromal cell (BMSC) monolayer. The fibroblasts display a reduction in the percentage of cytoskeleton-associated EGFRs. Furthermore, EGF-induced tyrosine kinase activity is unaffected by the mutation. Cells expressing the mutant EGFRs hardly invade a BMSC monolayer upon EGF stimulation in contrast to cells expressing wild-type EGFRs. Using the same cells no difference was observed in PDGF-induced invasion, which ligand was as potent in both cell types as EGF was in wild-type cells. Inhibition of both the phosphatidyl inositol-3-kinase (PI-3-K) and lipoxygenase pathways in wild-type cells mimicked the effect of the ABD deletion. Our results point to an important role for the ABD of the EGFR in EGF-induced tissue invasion.
authors.affiliation: Department of Molecular Cell Biology, Utrecht University, The Netherlands. m_heyden@hubrecht.nl
authors.forename: M A
authors.initials: MA
authors.lastname: van der Heyden
authors.forename: P M
authors.initials: PM
authors.lastname: Van Bergen en Henegouwen
authors.forename: N
authors.initials: N
authors.lastname: de Ruiter
authors.forename: M A
authors.initials: MA
authors.lastname: Verdaasdonk
authors.forename: J G
authors.initials: JG
authors.lastname: van den Tweel
authors.forename: G
authors.initials: G
authors.lastname: Rijksen
authors.forename: J
authors.initials: J
authors.lastname: Boonstra
authors.forename: P
authors.initials: P
authors.lastname: Joling
mesh_terms: D016475:3T3 Cells; D000199:Actins / Q000378:metabolism*; D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D001854:Bone Marrow Cells; D002448:Cell Adhesion / Q000502:physiology; D002465:Cell Movement / Q000502:physiology*; D002478:Cells, Cultured; D018920:Coculture Techniques; D003599:Cytoskeleton / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009637:Masoprocol / Q000494:pharmacology; D051379:Mice; D009361:Neoplasm Invasiveness; D019869:Phosphatidylinositol 3-Kinases; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors / Q000502:physiology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D000077191:Wortmannin
chemical_list: D000199:Actins; D000730:Androstadienes; D004791:Enzyme Inhibitors; D016859:Lipoxygenase Inhibitors; D010982:Platelet-Derived Growth Factor; D004815:Epidermal Growth Factor; D009637:Masoprocol; D019869:Phosphatidylinositol 3-Kinases; D017853:Phosphotransferases (Alcohol Group Acceptor); D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077191:Wortmannin